239 related articles for article (PubMed ID: 30701731)
1. PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases.
Lankin VZ; Tikhaze AK; Viigimaa M; Chazova IЕ
Ter Arkh; 2018 Sep; 90(9):27-30. PubMed ID: 30701731
[TBL] [Abstract][Full Text] [Related]
2. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ
Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224
[TBL] [Abstract][Full Text] [Related]
3. Effect of Evolocumab on Coronary Plaque Composition.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJP; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Honda S; Shishikura D; Scherer DJ; Borgman M; Brennan DM; Wolski K; Nissen SE
J Am Coll Cardiol; 2018 Oct; 72(17):2012-2021. PubMed ID: 30336824
[TBL] [Abstract][Full Text] [Related]
4. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
[TBL] [Abstract][Full Text] [Related]
5. Results of the GLAGOV trial.
Nissen SE; Nicholls SJ
Cleve Clin J Med; 2017 Dec; 84(12 Suppl 4):e1-e5. PubMed ID: 29281604
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
7. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
8. [PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
Thiery J; Burkhardt R
Herz; 2016 Jun; 41(4):281-9. PubMed ID: 27215417
[TBL] [Abstract][Full Text] [Related]
9. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
10. Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia.
Leucker TM; Gerstenblith G; Schär M; Brown TT; Jones SR; Afework Y; Weiss RG; Hays AG
J Am Heart Assoc; 2020 Jul; 9(14):e016263. PubMed ID: 32674634
[TBL] [Abstract][Full Text] [Related]
11. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
12. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome.
Yano H; Horinaka S; Ishimitsu T
J Cardiol; 2020 Mar; 75(3):289-295. PubMed ID: 31495548
[TBL] [Abstract][Full Text] [Related]
13. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option.
Pokrywka GS
Postgrad Med; 2018 Apr; 130(3):287-298. PubMed ID: 29411675
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
15. A safety evaluation of evolocumab.
Roth EM
Expert Opin Drug Saf; 2018 Jan; 17(1):99-106. PubMed ID: 28988500
[TBL] [Abstract][Full Text] [Related]
16. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
17. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
18. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
19. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.
Sattar N; Preiss D; Robinson JG; Djedjos CS; Elliott M; Somaratne R; Wasserman SM; Raal FJ
Lancet Diabetes Endocrinol; 2016 May; 4(5):403-10. PubMed ID: 26868195
[TBL] [Abstract][Full Text] [Related]
20. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
